Glucagon-like peptide-1 agonist

Where the papers sit

74 papers from the last 6 months study glucagon-like peptide-1 agonist directly · updated from PubMed 12 Oct 2026

• Real-World GLP-1 Outcomes

  GLP-1 receptor agonist research is extending beyond glycemic control to atrial fibrillation, cardiovascular mortality, fractures, asthma, cognition and mental health. Other analyses examine pancreatic cancer, hematologic malignancies, Crohn's disease and alcohol-related hospitalisation. Comparative cohorts generally seek safer, broader indications rather than a single disease endpoint. Confounding and inconsistent findings leave the long-term balance of benefits and risks unresolved.

  15 papers · 20.3%

• Real-World Diabetes Treatment

  Comparative real-world use is weighing GLP-1 receptor agonists against SGLT2 inhibitors and DPP-4 inhibitors for cardiovascular, renal and survival outcomes in type 2 diabetes. Safety work tracks gastrointestinal motility, suicidality, hair loss and cancer signals. Adherence, treatment patterns, affordability and return on investment are becoming part of effectiveness. Evidence remains observational, and access varies widely across settings.

  13 papers · 17.6%

• Obesity Weight Management

  Obesity treatment is moving toward durable, supported use of semaglutide and tirzepatide alongside health-behaviour therapy and, when needed, bariatric procedures. Real-world studies examine recurrent weight gain, cardiovascular-kidney-metabolic progression, prescribing in children and aesthetic effects after weight loss. Cost, financing, telehealth support and long-term healthcare utilization increasingly shape access and value. Co-agonists and amyloid-related mechanisms remain emerging extensions beyond established weight-loss outcomes.

  12 papers · 16.2%

• Broad GLP-1 Clinical Applications

  Clinical development is broadening GLP-1 therapy across adolescent obesity, cardiovascular disease, pulmonary hypertension, diabetic cardiomyopathy and post-COVID pulmonary fibrosis. Oral nonpeptide treatment and longer-acting agonists are moving beyond injectable therapy, while switching patterns and digital support address persistence. Hemodynamic and metabolic responses provide early mechanistic evidence in cardiac and pulmonary disease. Several indications remain exploratory, supported by protocols, early trials or real-world cohorts.

  11 papers · 14.9%

• GLP-1 in Fatty Liver Disease

  GLP-1 therapy is being directed toward metabolic dysfunction-associated steatotic liver disease, with attention to liver injury, inflammation, steatohepatitis and fibrosis. Biochemical and imaging outcomes are being used to test whether weight and glycemic benefits translate into hepatic improvement. Broader gut-pancreatic peptide combinations may expand treatment beyond single agonists, while transplant cohorts examine weight trajectories after liver replacement. Evidence remains mixed across clinical, mechanistic and preclinical work, including proposed effects on metastatic progression.

  9 papers · 12.2%

• GLP-1 Treatment Engagement

  GLP-1 care is increasingly focused on persistence, discontinuation, patient competence and the support needed after prescribing. Early clinical development adds long-acting agents for people without diabetes, while real-world cohorts assess kidney transplant, hemodialysis and inflammatory disease populations. Kidney outcomes appear heterogeneous, and biomarker improvements in anemia and inflammation need confirmation. Primary-care attitudes and treatment engagement remain important barriers to sustained benefit.

  8 papers · 10.8%

• Diabetes Treatment Intensification

  Type 2 diabetes care is refining when to move beyond GLP-1-based therapy, with insulin initiation and injectable treatment sequencing central to the clinical question. Comparisons with DPP-4 inhibitors focus on neuropathic complications and postoperative outcomes. Lentiviral GLP-1 gene therapy seeks β-cell regeneration, while PROTAC-mediated DPP-4 degradation represents a separate experimental strategy. The field therefore spans pragmatic treatment escalation and early disease-modifying approaches.

  6 papers · 8.1%